Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957984 | 0.87 | DRD2 (0.56) | DRD2KCNH2PRMT5WDR77HRH1 | |
| SCHEMBL6489547 | 0.80 | ABCB1 (0.53) | ABCB1ABCG2 | |
| SCHEMBL6493156 | 0.80 | GRIN1 (0.49) | ABCB1ABCG2 | |
| SCHEMBL6970695 | 0.79 | DRD4 (0.46) | DRD2KCNH2HRH1 | |
| SCHEMBL6638799 | 0.79 | HRH1 (0.43) | DRD2KCNH2HRH1 | |
| SCHEMBL6636318 | 0.79 | HRH1 (0.43) | DRD2KCNH2HRH1 | |
| SCHEMBL6489490 | 0.75 | ABCB1 (0.45) | PRMT5WDR77ABCB1ABCG2 | |
| SCHEMBL6961377 | 0.75 | KDM4E (0.53) | — | |
| SCHEMBL1953020 | 0.74 | DRD2 (0.46) | DRD2ABCB1ABCG2 | |
| SCHEMBL21412795 | 0.74 | SIGMAR1 (0.59) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | DRD2 2927/4885KCNH2 1952/4885PRMT5 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.